Department of Cardiovascular Medicine, Tohoku University, Sendai, Japan.
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Centre, Suita, Japan.
ESC Heart Fail. 2024 Aug;11(4):2344-2353. doi: 10.1002/ehf2.14790. Epub 2024 Apr 29.
The incidence and prognosis of symptomatic heart failure following acute myocardial infarction (AMI) in the primary percutaneous coronary intervention era have rarely been reported in the literature. This study aimed to (i) determine the incidence of heart failure admission among AMI survivors, (ii) compare 1 year outcomes between patients with heart failure admission and those without, and (iii) identify the independent risk factors associated with heart failure admission.
The Japan Acute Myocardial Infarction Registry is a prospective multicentre registry from which data on consecutively enrolled patients with AMI from 50 institutions between 2015 and 2017 were obtained. Among the 3411 patients enrolled, 3226 who survived until discharge were included in this study. The primary endpoint was all-cause mortality. The secondary endpoints were major adverse cardiovascular events (defined as cardiovascular mortality, non-fatal myocardial infarction, or non-fatal cerebral infarction) and major bleeding events corresponding to Bleeding Academic Research Consortium Type 3 or 5. Clinical outcomes were compared between the patients who were and were not admitted for heart failure. Over a median follow-up of 12 months, 124 patients (3.8%) were admitted due to heart failure. Independent risk factors for heart failure admission included older age, female sex, Killip class ≥2 on admission, left ventricular ejection fraction <40%, estimated glomerular filtration rate ≤30 mL/min/1.73 m, a history of malignancy, and non-use of angiotensin-converting enzyme inhibitors at discharge. The cumulative incidence of all-cause mortality was significantly higher in the heart failure admission group than in the no heart failure admission group (11.3% vs. 2.5%, P < 0.001). The rates of major adverse cardiovascular events (16.9% vs. 2.7%, P < 0.001) and major bleeding (6.5% vs. 1.6%, P < 0.001) were significantly higher in the heart failure admission group. Heart failure admission was associated with a higher risk of all-cause mortality, even after adjusting for potential confounders (adjusted hazard ratio: 2.41, 95% confidence interval: 1.33-4.39, P = 0.004).
Utilizing real-world data of the contemporary percutaneous coronary intervention era from the Japan Acute Myocardial Infarction Registry database, this study demonstrates that the heart failure admission of AMI survivors was significantly associated with higher all-cause mortality rates.
在经皮冠状动脉介入治疗时代,急性心肌梗死(AMI)后出现有症状心力衰竭的发生率和预后很少有文献报道。本研究旨在:(i)确定 AMI 幸存者中心力衰竭入院的发生率;(ii)比较心力衰竭入院患者和无心力衰竭入院患者的 1 年结局;(iii)确定与心力衰竭入院相关的独立危险因素。
日本急性心肌梗死注册研究是一项前瞻性多中心注册研究,从中获取了 2015 年至 2017 年 50 家机构连续纳入的 AMI 患者的数据。在纳入的 3411 例患者中,有 3226 例存活至出院,被纳入本研究。主要终点为全因死亡率。次要终点为主要心血管不良事件(定义为心血管死亡、非致命性心肌梗死或非致命性脑梗死)和对应于 Bleeding Academic Research Consortium 类型 3 或 5 的主要出血事件。比较了心力衰竭入院患者和无心力衰竭入院患者的临床结局。在中位随访 12 个月期间,有 124 例(3.8%)患者因心力衰竭入院。心力衰竭入院的独立危险因素包括年龄较大、女性、入院时 Killip 分级≥2、左心室射血分数<40%、估算肾小球滤过率≤30ml/min/1.73m、恶性肿瘤病史和出院时未使用血管紧张素转换酶抑制剂。心力衰竭入院组的全因死亡率明显高于无心力衰竭入院组(11.3% vs. 2.5%,P<0.001)。心力衰竭入院组的主要心血管不良事件(16.9% vs. 2.7%,P<0.001)和主要出血事件(6.5% vs. 1.6%,P<0.001)发生率明显更高。即使在调整了潜在混杂因素后,心力衰竭入院与全因死亡率升高相关(调整后的危险比:2.41,95%置信区间:1.33-4.39,P=0.004)。
利用日本急性心肌梗死注册研究数据库中的当代经皮冠状动脉介入治疗时代的真实世界数据,本研究表明,AMI 幸存者的心力衰竭入院与更高的全因死亡率显著相关。